Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Dec 18

PMID 33333774

Citations 36

Authors

Daniil Grinchii

Eliyahu Dremencov

Affiliations

Soon will be listed here.

Abstract

Atypical antipsychotic drugs were introduced in the early 1990s. Unlike typical antipsychotics, which are effective only against positive symptoms of schizophrenia, atypical antipsychotics are effective against negative and cognitive symptoms as well. Furthermore, they are effective not only in psychotic but also in affective disorders, on their own or as adjuncts to antidepressant drugs. This review presents the neural mechanisms of currently existing atypical antipsychotics and putative antipsychotics currently being investigated in preclinical and clinical studies and how these relate to their effectiveness in mood disorders such as depression, anxiety, and post-traumatic stress disorder (PTSD). Typical antipsychotics act almost exclusively on the dopamine system. Atypical drugs, however, modulate serotonin (5-HT), norepinephrine, and/or histamine neurotransmission as well. This multimodal mechanism of action putatively underlies the beneficial effect of atypical antipsychotics in mood and anxiety disorders. Interestingly, novel experimental drugs having dual antipsychotic and antidepressant therapeutic potential, such as histamine, adenosine, and trace amine-associated receptors (TAAR) ligand, are also characterized by a multimodal stimulatory effect on central 5-HT, norepinephrine, and/or histamine transmission. The multimodal stimulatory effect on central monoamine neurotransmission may be thus primarily responsible for the combined antidepressant and antipsychotic therapeutic potential of certain central nervous system (CNS) drugs.

Citing Articles

Clinical practice guidelines on the assessment and management of cognitive impairment in major depressive disorder.

Singh O, Avinash P, Gautam A, Prasad A, Jagawat T Indian J Psychiatry. 2025; 67(1):98-105.

PMID: 40046482 PMC: 11878465. DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_563_24.

The Advances in Antipsychotics-Induced Dyskinesia Rodent Models: Benefits of Antioxidant Supplementation.

Velickovic U, Selakovic D, Jovicic N, Mitrovic M, Janjic V, Rosic S Biomedicines. 2025; 13(2).

PMID: 40002925 PMC: 11853207. DOI: 10.3390/biomedicines13020512.

Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds.

Biso L, Carli M, Scarselli M, Longoni B Biomedicines. 2025; 13(1).

PMID: 39857669 PMC: 11763187. DOI: 10.3390/biomedicines13010085.

Haloperidol-Induced Catalepsy and Its Correlations with Acetylcholinesterase Activity in Different Brain Structures of Mice.

Silva B, Lima J, Echeverry M, Alberto-Silva C Neurol Int. 2024; 16(6):1731-1741.

PMID: 39728751 PMC: 11678777. DOI: 10.3390/neurolint16060125.

Optimizing Chronotherapy in Psychiatric Care: The Impact of Circadian Rhythms on Medication Timing and Efficacy.

Colita C, Hermann D, Filfan M, Colita D, Doepnner T, Tica O Clocks Sleep. 2024; 6(4):635-655.

PMID: 39584972 PMC: 11586979. DOI: 10.3390/clockssleep6040043.

References

Diaz-Cabiale Z, Hurd Y, Guidolin D, Finnman U, Zoli M, Agnati L . Adenosine A2A agonist CGS 21680 decreases the affinity of dopamine D2 receptors for dopamine in human striatum. Neuroreport. 2001; 12(9):1831-4. DOI: 10.1097/00001756-200107030-00014. View

Brown R, Taylor M, Geddes J . Aripiprazole alone or in combination for acute mania. Cochrane Database Syst Rev. 2013; (12):CD005000. PMC: 11330668. DOI: 10.1002/14651858.CD005000.pub2. View

Revel F, Moreau J, Gainetdinov R, Bradaia A, Sotnikova T, Mory R . TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci U S A. 2011; 108(20):8485-90. PMC: 3101002. DOI: 10.1073/pnas.1103029108. View

Kim S, Fristrup P, Abrol R, Goddard 3rd W . Structure-based prediction of subtype selectivity of histamine H3 receptor selective antagonists in clinical trials. J Chem Inf Model. 2011; 51(12):3262-74. PMC: 3246544. DOI: 10.1021/ci200435b. View

Burnstock G . Purinergic Signalling and Neurological Diseases: An Update. CNS Neurol Disord Drug Targets. 2016; 16(3):257-265. DOI: 10.2174/1871527315666160922104848. View

El Mansari M, Guiard B, Chernoloz O, Ghanbari R, Katz N, Blier P . Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder. CNS Neurosci Ther. 2010; 16(3):e1-17. PMC: 2904493. DOI: 10.1111/j.1755-5949.2010.00146.x. View

Domenici M, Ferrante A, Martire A, Chiodi V, Pepponi R, Tebano M . Adenosine A receptor as potential therapeutic target in neuropsychiatric disorders. Pharmacol Res. 2019; 147:104338. DOI: 10.1016/j.phrs.2019.104338. View

Lenze E, Mulsant B, Blumberger D, Karp J, Newcomer J, Anderson S . Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet. 2015; 386(10011):2404-12. PMC: 4690746. DOI: 10.1016/S0140-6736(15)00308-6. View

Flik G, Folgering J, Cremers T, Westerink B, Dremencov E . Interaction Between Brain Histamine and Serotonin, Norepinephrine, and Dopamine Systems: In Vivo Microdialysis and Electrophysiology Study. J Mol Neurosci. 2015; 56(2):320-8. DOI: 10.1007/s12031-015-0536-3. View

10.

Stark A, Jordan S, Allers K, Bertekap R, Chen R, Mistry Kannan T . Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl). 2007; 190(3):373-82. DOI: 10.1007/s00213-006-0621-y. View

11.

Perez-Garcia C, Morales L, Cano M, Sancho I, Alguacil L . Effects of histamine H3 receptor ligands in experimental models of anxiety and depression. Psychopharmacology (Berl). 1999; 142(2):215-20. DOI: 10.1007/s002130050882. View

12.

Revel F, Meyer C, Bradaia A, Jeanneau K, Calcagno E, Andre C . Brain-specific overexpression of trace amine-associated receptor 1 alters monoaminergic neurotransmission and decreases sensitivity to amphetamine. Neuropsychopharmacology. 2012; 37(12):2580-92. PMC: 3473323. DOI: 10.1038/npp.2012.109. View

13.

Szabo S, De Montigny C, Blier P . Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. Br J Pharmacol. 1999; 126(3):568-71. PMC: 1565850. DOI: 10.1038/sj.bjp.0702343. View

14.

Chernoloz O, El Mansari M, Blier P . Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder. Psychopharmacology (Berl). 2009; 206(2):335-44. DOI: 10.1007/s00213-009-1611-7. View

15.

Dremencov E, El Mansari M, Blier P . Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol Psychiatry. 2006; 61(5):671-8. DOI: 10.1016/j.biopsych.2006.05.015. View

16.

SCHOTTE A, Janssen P, Gommeren W, Luyten W, Van Gompel P, Lesage A . Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996; 124(1-2):57-73. DOI: 10.1007/BF02245606. View

17.

Ferre S, Popoli P, Rimondini R, Reggio R, Kehr J, Fuxe K . Adenosine A2A and group I metabotropic glutamate receptors synergistically modulate the binding characteristics of dopamine D2 receptors in the rat striatum. Neuropharmacology. 1999; 38(1):129-40. DOI: 10.1016/s0028-3908(98)00154-3. View

18.

Chwieduk C, Scott L . Asenapine: a review of its use in the management of mania in adults with bipolar I disorder. CNS Drugs. 2011; 25(3):251-67. DOI: 10.2165/11206700-000000000-00000. View

19.

Escudero M, Gutierrez-Rojas L, Lahera G . Second Generation Antipsychotics Monotherapy as Maintenance Treatment for Bipolar Disorder: a Systematic Review of Long-Term Studies. Psychiatr Q. 2020; 91(4):1047-1060. DOI: 10.1007/s11126-020-09753-2. View

20.

Guiard B, El Mansari M, Merali Z, Blier P . Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol. 2008; 11(5):625-39. DOI: 10.1017/S1461145707008383. View